14-year trial shows that prostate cancer screening reduces deaths by almost half or clues such as pre-cancerous cells – is strongly encouraged as a way of improving public health. However, there are doubts as to whether the benefits of screening outweighs the negatives. Over-diagnosis is one of the biggest worries. Since the number of people who [...]
Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). TMX-101 is an immunotherapeutic compound and Telormedix has already recruited [...]
The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after [...]
CytRx Corporation, a biopharmaceutical company specializing in oncology, announced that its drug candidate bafetinib (formerly known as INNO- 406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Source: General Cancer News Articles Provided by Cancer Compass
ARIAD Pharmaceuticals, Inc. announced that the independent Data Monitoring Committee (DMC) of the Phase 3 SUCCEED trial has completed the second interim efficacy analysis as specified in the study protocol and has recommended that the randomized, placebo-controlled trial of oral ridaforolimus in patients with metastatic sarcomas continue to [...]
GTx, Inc. announced top line results of the Phase III clinical trial evaluating toremifene 20 mg, a selective estrogen receptor modulator, for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia, or PIN, a premalignant lesion of the prostate. Source: General Cancer News Articles Provided by [...]
Synta Pharmaceuticals Corp. announced that clinical activity seen in the first stage of its trial for STA-9090 in Stage IIIB and Stage IV patients with non-small cell lung cancer (NSCLC), support advancing to the second stage of the trial. This result was achieved in the first pre-defined patient cohort [...]
Celldex Therapeutics, Inc. announced that the first patient has been screened in a randomized Phase 2 study of the Company’s novel, first-in- class antibody-based vaccine candidate from its Precision Targeted Immunotherapy (PTI) platform. Source: General Cancer News Articles Provided by Cancer Compass
Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, [...]
The first trial of an important new combination therapy of treatment with the chemotherapy drug pemetrexed concurrent with radiation in lung cancer has delivered promising results, French researchers report at the 2nd European Lung Cancer Conference. Source: General Cancer News Articles Provided by Cancer Compass